Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.42 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503951 | 0.91 | DRD2 (0.40) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL8203575 | 0.90 | DRD2 (0.45) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL8191001 | 0.89 | ADRA1D (0.51) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6499248 | 0.86 | DGAT1 (0.48) | SIGMAR1DRD2CCR5DGAT1 | |
| SCHEMBL7129359 | 0.84 | APP (0.42) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7127231 | 0.84 | SIGMAR1 (0.46) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11736837 | 0.82 | SMN1; SMN2 (0.47) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL8203318 | 0.82 | SMN1; SMN2 (0.43) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6489774 | 0.79 | HTR7 (0.43) | SIGMAR1DRD2CCR5 | |
| SCHEMBL8192351 | 0.79 | OPRM1 (0.47) | SIGMAR1DRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998036749-A1 | TETRALONE DERIVATIVES AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-27 | — | — | WO | claimed |
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| US-6664250-B2 | Cardiovascular disorders | BRISTOL-MYERS SQUIBB CO. | 2003-12-16 | — | — | US | disclosed |
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | S ATWAL KARNAIL (US) | 2003-06-19 | — | — | US | disclosed |
| EP-1129072-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-05 | — | — | EP | disclosed |
| US-6262068-B1 | ISOQUINOLONES | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
| WO-2000027815-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | SMITHKLINE BEECHAM SPA (IT) | 2000-05-18 | — | — | WO | disclosed |
| US-6048877-A | Tetralone derivatives as antiarrhythmic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-11 | — | — | US | disclosed |
| WO-1998036749-A1 | TETRALONE DERIVATIVES AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | SIGMAR1 50/4885DRD2 1194/4885HTR2A 1914/4885 |
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | NPR3, SCN3A, NRDC | SIGMAR1 316/4885DRD2 1143/4885HTR2A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.